Sign In
Buy BMY
$54.72
+0.260 (+0.477%)
At Close: Jun 03, 2026
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Thursday, 23'rd Oct 2025
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The Play On Bristol-Myers Squibb
11:27am, Tuesday, 21'st Oct 2025
Bristol-Myers Squibb has had a recent 30% stock decline amid concerns over patent expirations for key blockbuster drugs through 2028. Despite two FY25 outlook raises and strong cash flow, BMY's revenu
Will BMY's Growth Portfolio Drive Third-Quarter Results?
10:01am, Tuesday, 21'st Oct 2025
Bristol Myers leans on new drugs like Opdivo and Reblozyl to offset pressure from generics as its Growth Portfolio drives stability.
Rates Going Lower Next Week: Our Top 5% Dividend Picks Could Soar
08:43am, Tuesday, 21'st Oct 2025
Investors love dividend stocks, especially those with high yields, because they provide a substantial income stream and offer significant total return potential.
My Top 3 Pharma Stocks
11:38am, Monday, 20'th Oct 2025
Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and o
October's 5 Dividend Growth Stocks With Yields Up To 8.33%
11:34am, Monday, 20'th Oct 2025
Every month, we screen for high-yield dividend yields, but those that also deliver relatively consistent growth with regular dividend increases. The parameters of the screening also include dividend s
2 High-Yield Dividend Stocks Too Cheap to Ignore
10:57am, Sunday, 19'th Oct 2025
What's even better than a solid, reliable dividend stock? A solid, reliable, high-yield dividend stock.
REDMOND, Wash. and PRINCETON, N.J.
Final Trade: WMT, AMZN, F, BMY
06:20pm, Tuesday, 14'th Oct 2025
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
BMY Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?
11:06am, Tuesday, 14'th Oct 2025
Shares of Bristol Myers BMY continue to lose momentum in 2025. In fact, the stock lost 4.7% in a month against the industry's gain of 4.8%.
Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio?
09:51am, Monday, 13'th Oct 2025
Bristol Myers' $1.5B buyout of Orbital Therapeutics expands its cell therapy reach with a next-gen in vivo CAR T candidate and advanced RNA platform.
Stock Looks Undervalued As Bristol Myers Buys Orbital Therapeutics
07:30am, Monday, 13'th Oct 2025
Bristol Myers Squibb remains undervalued, ranking 12th on my Magic Formula screen with strong earnings yield and capital returns amongst the S&P 500. Company pivoting from small-molecule drugs to mRNA
Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types
06:59am, Monday, 13'th Oct 2025
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ESMO--Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types.
SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration
05:00am, Monday, 13'th Oct 2025
REDMOND, Wash. , Oct. 13, 2025 /PRNewswire/ -- SystImmune, Inc., a clinical-stage biotechnology company, today announced the treatment of the first patient in the IZABRIGHT-Breast01 study (NCT06926868
Bristol Myers Squibb: Value Emerges From Distress
09:52am, Saturday, 11'th Oct 2025
Bristol Myers Squibb offers a compelling value entry for long-term income investors, despite looming patent cliffs and execution risks. BMY's growth portfolio is positioned to offset revenue losses fr
